Amneal shareholders approve acquisition of Kashiv BioSciences; closing expected H2 2026

Amneal Pharmaceuticals, Inc.

Stockholders approved Purchase Agreement to acquire 100% of Kashiv BioSciences membership interests.
Approved issuance of 28,942,108 shares of Class A common stock to Sellers in connection with the deal.
Vote results: Transaction Proposal 138,265,079 for, 655,759 against, 67,147 abstain; Stock Issuance Proposal 286,714,072 for, 1,791,016 against, 62,071 abstain.
Closing expected in second half of 2026, subject to remaining conditions.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.